Literature DB >> 29778260

Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Brianna L Norton1, Matthew J Akiyama2, Philippe J Zamor3, Alain H Litwin2.   

Abstract

Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry the highest burden, few have initiated treatment. We present a comprehensive review of the evidence on the efficacy of HCV medications, drug-drug interactions, and barriers to and models of care. Studies have demonstrated comparable efficacy for individuals who are on opioid agonist therapy compared with those who are not. We propose that a strategy of treatment and cure-as-prevention is imperative in this population to curb the hepatitis C epidemic.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Best practice; Direct acting antivirals; Drug-drug interactions; Hepatitis C virus; Opioid agonist therapy

Mesh：

Substances：

Year:  2018        PMID： 29778260      PMCID： PMC6022838          DOI： 10.1016/j.idc.2018.02.001

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  85 in total

Review 1.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

2.  Successful integration of hepatitis C evaluation and treatment services with methadone maintenance.

Authors:  Kenneth A Harris; Julia H Arnsten; Alain H Litwin
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

Review 3.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

4.  Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.

Authors:  Alain H Litwin; Irene Soloway; Marc N Gourevitch
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

5.  Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-05-06       Impact factor: 17.586

6.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

7.  Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs.

Authors:  Marcus A Bachhuber; Chinazo O Cunningham
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

8.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

Authors:  Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten
Journal:  J Subst Abuse Treat       Date:  2008-11-28

9.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

Review 10.  Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.

Authors:  Sivi Ouwerkerk-Mahadevan; Jan Snoeys; Monika Peeters; Maria Beumont-Mauviel; Alexandru Simion
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447
View more
  11 in total

1.  HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges.

Authors:  Sabrina A Assoumou; Samantha M Paniagua; Priscilla Gonzalez; Jianing Wang; Curt G Beckwith; Laura F White; Jessica L Taylor; Kristen Coogan; Jeffrey H Samet; Benjamin P Linas
Journal:  AIDS Behav       Date:  2021-03-22

2.  Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.

Authors:  Christer F Aas; Jørn Henrik Vold; Svetlana Skurtveit; Ingvild Odsbu; Fatemeh Chalabianloo; Aaron G Lim; Kjell Arne Johansson; Lars Thore Fadnes
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-06-30

3.  Declines in Depressive Symptoms Among People who Inject Drugs Treated With Direct-Acting Antivirals While on Opioid Agonist Therapy.

Authors:  Irene Pericot-Valverde; Moonseong Heo; Jiajing Niu; Brianna L Norton; Matthew J Akiyama; Linda Agyemang; Alain H Litwin
Journal:  Open Forum Infect Dis       Date:  2020-10-10       Impact factor: 3.835

4.  Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).

Authors:  Markus Cornberg; Albrecht Stoehr; Uwe Naumann; Gerlinde Teuber; Hartwig Klinker; Thomas Lutz; Hjördis Möller; Dennis Hidde; Kristina Lohmann; Karl-Georg Simon
Journal:  Viruses       Date:  2022-07-14       Impact factor: 5.818

5.  Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic.

Authors:  Phyllis Losikoff; Jordon D Bosse; Stephen A Martin; Amanda Wilson; Lisa M Chiodo
Journal:  Front Psychiatry       Date:  2022-09-14       Impact factor: 5.435

6.  "Sobriety equals getting rid of hepatitis C": A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults.

Authors:  Taylor A Vega; Ximena A Levander; Andrew Seaman; P Todd Korthuis; Honora Englander
Journal:  J Subst Abuse Treat       Date:  2021-02-25

7.  A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment.

Authors:  A Seaman; C A King; T Kaser; A Geduldig; W Ronan; R Cook; B Chan; X A Levander; K C Priest; P T Korthuis
Journal:  Int J Drug Policy       Date:  2021-07-27

8.  On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017.

Authors:  Christer Frode Aas; Jørn Henrik Vold; Svetlana Skurtveit; Ingvild Odsbu; Fatemeh Chalabianloo; Jan Magnus Økland; Rafael Alexander Modahl Leiva; Peter Vickerman; Kjell Arne Johansson; Lars T Fadnes
Journal:  BMJ Open       Date:  2020-08-26       Impact factor: 2.692

9.  From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe.

Authors:  Julian Surey; Dee Menezes; Marie Francis; John Gibbons; Binta Sultan; Ala Miah; Ibrahim Abubakar; Alistair Story
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

10.  Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.

Authors:  Anishaa Sivakumar; Lynn Madden; Elizabeth DiDomizio; Anthony Eller; Merceditas Villanueva; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2021-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.